CN104435318B - A kind of extracting method for treating hemorrhagic stroke Chinese medical extract components group and application - Google Patents
A kind of extracting method for treating hemorrhagic stroke Chinese medical extract components group and application Download PDFInfo
- Publication number
- CN104435318B CN104435318B CN201410734891.3A CN201410734891A CN104435318B CN 104435318 B CN104435318 B CN 104435318B CN 201410734891 A CN201410734891 A CN 201410734891A CN 104435318 B CN104435318 B CN 104435318B
- Authority
- CN
- China
- Prior art keywords
- chinese medical
- medical extract
- hemorrhagic stroke
- parts
- components group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 44
- 208000016988 Hemorrhagic Stroke Diseases 0.000 title claims abstract description 17
- 208000020658 intracerebral hemorrhage Diseases 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 22
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229930182470 glycoside Natural products 0.000 claims abstract description 13
- -1 Paeonol glycoside Chemical class 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000000605 extraction Methods 0.000 claims abstract description 11
- 229930182489 iridoid glycoside Natural products 0.000 claims abstract description 9
- 229930182490 saponin Natural products 0.000 claims abstract description 9
- 150000007949 saponins Chemical class 0.000 claims abstract description 9
- 235000017709 saponins Nutrition 0.000 claims abstract description 9
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims abstract description 9
- 240000005001 Paeonia suffruticosa Species 0.000 claims abstract description 8
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims abstract description 8
- 150000004056 anthraquinones Chemical class 0.000 claims abstract description 8
- 150000008145 iridoid glycosides Chemical class 0.000 claims abstract description 8
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 claims abstract description 8
- UILPJVPSNHJFIK-UHFFFAOYSA-N p-methoxy-o-hydroxyacetophenone Natural products COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 claims abstract description 8
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 241000405414 Rehmannia Species 0.000 claims abstract description 7
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 6
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 6
- 240000004980 Rheum officinale Species 0.000 claims abstract description 6
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 6
- 241000736199 Paeonia Species 0.000 claims abstract description 5
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 5
- 150000002338 glycosides Chemical class 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 229940079593 drug Drugs 0.000 claims description 11
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 7
- 239000000470 constituent Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 2
- 235000018553 tannin Nutrition 0.000 abstract description 8
- 229920001864 tannin Chemical class 0.000 abstract description 8
- 239000001648 tannin Chemical class 0.000 abstract description 8
- 102000008946 Fibrinogen Human genes 0.000 abstract description 7
- 108010049003 Fibrinogen Proteins 0.000 abstract description 7
- 229940012952 fibrinogen Drugs 0.000 abstract description 7
- 238000011699 spontaneously hypertensive rat Methods 0.000 abstract description 4
- 101001058233 Rattus norvegicus Gamma-enolase Proteins 0.000 abstract description 2
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 8
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 101710191797 Gamma-enolase Proteins 0.000 description 5
- 102100028652 Gamma-enolase Human genes 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical class C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002021 butanolic extract Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 102000011425 S100 Calcium Binding Protein beta Subunit Human genes 0.000 description 1
- 108010023918 S100 Calcium Binding Protein beta Subunit Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229930182487 phenolic glycoside Natural products 0.000 description 1
- 150000007950 phenolic glycosides Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000008678 sanqi Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of extracting method for treating hemorrhagic stroke Chinese medical extract components group and its application.Rheum officinale, the root bark of tree peony, the radix paeoniae rubrathe, the dried rhizome of rehmannia, pseudo-ginseng add water to cook extraction according to a certain weight ratio, after crushing, and with after dichloromethane extraction, water layer uses extracting n-butyl alcohol to extract again, and it is Chinese medical extract components group that butanol extraction liquid is reclaimed after doing.Chinese medical extract HPLC MS are analyzed by Chinese herbaceous peony glycoside, tannin class, Paeonol glycoside, Anthraquinones, stilbene class, saponins and iridoid glycosides 33 into being grouped into, male spontaneously hypertensive rat neuronspecific enolase, 100 β albumen of S, IL 1, TNF α, plasma fibrinogen level can be significantly reduced, can be used to prepare the purposes for the treatment of hemorrhagic stroke medicine.
Description
First, technical field
The present invention relates to technical field of Chinese medicine, specifically one kind treat hemorrhagic stroke Chinese medical extract components group
Extracting method and its application.
2nd, background technology
Hemorrhagic stroke (cerebral hemorrhage) is disease clinically common both at home and abroad, and the disease morbidity is hurried, and progress is rapid, dies of illness
Rate is high, and patient's prognosis situation directly influences life quality after being ill.Neuronspecific enolase (SNE) and S-100 β eggs
It is the important indicator for judging the cerebral lesion order of severity in vain, wherein, SNE is a mark of neuron and neuroendocrine cell
Enzyme, when brain tissue occurs hypoxic-ischemic, in cerebrospinal fluid, SNE levels are raised.S-100 β albumen is brain specific proteins, in serum
S-100 β protein levels are higher, and degree of cerebral damage is heavier.The method of current western medical treatment cerebral hemorrhage is that operative treatment and internal medicine are comprehensive
Two big class for the treatment of are closed, is had certain risk and curative effect is not notable enough.
The traditional Chinese medical science thinks that hemorrhagic stroke comes from stagnated heat in xuefen, and fight is not understood, impatency brain key, and makes heat symptoms caused by an exopathgen more vehement, Jin Erhua
The raw phlegm humorously of fire, causes stagnant heat resistance key, therefore based on being expelled the heat-evil with cool blood dissipates the stasis of blood, logical internal organs during treatment.Chinese herb rhubarb clearing heat-fire, the root bark of tree peony
Cool blood dissipates the stasis of blood, radix paeoniae rubrathe cooling and activating blood, Sanqi Tongmai stagnation resolvation, dried rhizome of rehmannia nourishing Yin and clearing heat.Therefore, the present invention is carried with these Chinese medicine compositions
Take and prepare Chinese medical extract, evaluated its anti-inflammatory, invigorate blood circulation and prevented and treated brain damage effect with spontaneous hypertensive rat, for treating out
The research and development of courageous and upright apoplexy medicine.
3rd, the content of the invention
For the demand of clinical Hemorrhage apoplexia, it is an object of the invention to provide a kind of have treatment hemorrhagic stroke
The extracting method of Chinese medical extract components group and its application.
The purpose of the present invention is realizing by following technical scheme：
1st, a kind of extracting method for treating hemorrhagic stroke Chinese medical extract components group, extraction step are as follows：
(1) bulk drug：Rheum officinale 1-5 parts, root bark of tree peony 1-5 parts, radix paeoniae rubrathe 1-5 parts, dried rhizome of rehmannia 1-8 parts, pseudo-ginseng 1-6 parts；
(2) above-mentioned raw materials medicinal powder is broken to into 20-40 mesh, plus 5-15 times is measured water and extracted twice, merging filtrate is concentrated into 0.5-
1.5g crude drugs/ml, measure dichloromethane with 1-3 times and extract 3-6 time, abandon dichloromethane layer, and water layer measures extracting n-butyl alcohol with 1-3 times again
3-6 time, merge butanol extraction liquid recovery and do as Chinese medical extract components group；
(3) Chinese medical extract constituent analysis：The chemical composition of Chinese medical extract is analyzed with HPLC-MS, mainly by Paeoniflorin
Class, tannin class, Paeonol glycoside, Anthraquinones, stilbene class, saponins and iridoid glycosides 33 are into being grouped into.
2nd, application of a kind of Chinese medical extract components group in treatment hemorrhagic stroke medicine is prepared.
Beneficial effect：
The Chinese medical extract components group of the present invention, mainly by Chinese herbaceous peony glycoside, tannin class, Paeonol glycoside, Anthraquinones, stilbene
Class, saponins and iridoid glycosides 33 can significantly reduce spontaneous hypertensive rat neuronal specificity alkene into being grouped into
Enolase, S-100 β albumen, IL-1, TNF-α, plasma fibrinogen level, can be used to prepare treatment hemorrhagic stroke medicine
Purposes.
4th, the pharmacological testing of Chinese medical extract components group
1. modeling and administration
Male spontaneously hypertensive rat is randomly divided into 4 groups, 8 per group, with Wistar male rats as blank control group
(physiological saline group), Hypertensive Rats are respectively model group (physiological saline group), and positive controls (aspirin group), Chinese medicine are carried
Take thing high and low dose group.Each group is pressed into 10mLkg-1Daily gastric infusion 1 time, continuous 15 days.After 15th day gastric infusion 1h
Arteria carotis takes blood 5ml in added with 0.038gml-1In the centrifuge tube of sodium citrate, with 3000rmin-1Rotating speed is centrifuged 10min,
Take upper plasma, Elisa kit measurement rat S-100B albumen, NSE, IL-1, TNF-α, plasma fibrinogen.
Statistics carries out the inspection of double sample t and variance analysis using SPSS13.0 statistical softwares to data, experimental data withRepresent.
2. the impact of couple S-100B and NSE
Experimental result (table 1) shows：Model group S-100B and NSE significantly raise (P ＜ 0.01) compared with blank group, with model group
Relatively, positive controls and Chinese medical extract various dose group can significantly reduce S-100B and NSE levels (P ＜ 0.01).
Impact of 1 Chinese medical extract of table to S-100B and NSE
Note：With blank group than ##P ﹤ 0.01；With model group than * * P ﹤ 0.01
3rd, the impact to inflammatory factor
Experimental result (table 2) shows：Spontaneously hypertensive rat model group IL-1, TNF-α level are significantly risen compared with blank group
High (P ＜ 0.01).Compare with model group, positive drug control group and Chinese medical extract high and low dose group can significantly reduce spontaneity
Hypertensive Rats IL-1, TNF-α level (P ＜ 0.01).
Impact of 2 Chinese medical extract of table to inflammatory factor
Note：Compare * * P ﹤ 0.01 with model group；Compare ##P ﹤ 0.01 with blank group
4th, the impact to plasma fibrinogen
Experimental result (table 3) shows：Male spontaneously hypertensive rat fibrinogen level is significantly raised compared with blank group
(P ＜ 0.01).Compare with model group, positive controls and Chinese medical extract high and low dose group can significantly reduce spontaneous high blood
Pressure male rat plasma fibrinogen level (P ＜ 0.01).
3 Chinese medical extract of table is to rat annulus proteinogen measurement result
Note：Compare * * P ﹤ 0.01 with model group；Compare ##P ﹤ 0.01 with blank group
5th, traditional Chinese medicine extraction chemical constituent HPLC-MS analyses
Chromatographic column (Thermo ODS-2HYPERSIL 250mm × 4.6mm)；10 μ L of sample size；Column temperature：35℃；Flow velocity is
1.0mL.min-1；Mobile phase：- 0.5% formic acid (B) of methyl alcohol (A), elution program is：0～10min, 22%～30%A；10～
25min, 30%～40%；25～30min, 40%～50%A；30～50min, 50%～62%A；Sample introduction 10ul；Detection ripple
It is long：254nm.Ion gun：Electron spray；Scanning of the mass spectrum mode：Anion；Atomization gas pressure：55psi；Auxiliary heating atmospheric pressure：
55psi；Air curtain pressure：40psi；Ionization temperature：550℃；Collision energy：10V；Capillary voltage：5500V；Remove cluster electricity
Pressure：-60V；Sweep limits：M/z50～1000.
Chinese medical extract Jing HPLC-MS are analyzed, and total ion current figure is shown in Fig. 1.By each chromatogram molecular ion peak and main broken
The parsing at piece peak reference literature, identify the Chinese medical extract mainly altogether by Chinese herbaceous peony glycoside, tannin class, Paeonol glycoside, anthracene
Quinones, stilbene class, saponins and iridoid glycosides 33 are into being grouped into (table 4).
4 n-butanol portion main chemical compositions of table
Result of study shows, by the Chinese medical extract of present invention preparation, mainly by Chinese herbaceous peony glycoside, tannin class, root bark of tree peony phenolic glycoside
Class, Anthraquinones, stilbene class, saponins and iridoid glycoside constituents etc. 33 can significantly reduce SH into being grouped into
Male rat neuronspecific enolase, S-100 β albumen, IL-1, TNF-α, plasma fibrinogen level, can be used for
Prepare the purposes for the treatment of hemorrhagic stroke medicine.
6th, illustrate
Fig. 1 Chinese medical extract HPLC-MS ion flow graphs.
Seven. specific embodiment
Embodiment 1：The extracting method of the Chinese medical extract components group for the treatment of hemorrhagic stroke, extraction step are as follows：
(1) bulk drug：1 part of rheum officinale, 1 part of the root bark of tree peony, 1 part of the radix paeoniae rubrathe, 1 part of the dried rhizome of rehmannia, 1 part of pseudo-ginseng；
(2) above-mentioned raw materials medicinal powder is broken to into 20 mesh, plus 5 times of amount water is extracted twice, merging filtrate, be concentrated into 0.5g crude drugs/
Ml, is extracted 3 times with 1 times of amount dichloromethane, abandons dichloromethane layer, and water layer is again with 1 times of amount extracting n-butyl alcohol 3 times, merging n-butanol
Extract is reclaimed and is done as Chinese medical extract components group；
(3) Chinese medical extract constituent analysis：The chemical composition of Chinese medical extract is analyzed with HPLC-MS, mainly by Paeoniflorin
Class, tannin class, Paeonol glycoside, Anthraquinones, stilbene class, saponins and iridoid glycosides 33 are into being grouped into.
Embodiment 2：The extracting method of the Chinese medical extract components group for the treatment of hemorrhagic stroke, extraction step are as follows：
(1) bulk drug：2 parts of rheum officinale, 3 parts of the root bark of tree peony, 3 parts of the radix paeoniae rubrathe, 5 parts of the dried rhizome of rehmannia, 3 parts of pseudo-ginseng；
(2) above-mentioned raw materials medicinal powder is broken to into 30 mesh, plus 10 times of amount water is extracted twice, merging filtrate, be concentrated into 1.0g crude drugs/
Ml, is extracted 4 times with 2 times of amount dichloromethane, abandons dichloromethane layer, and water layer is again with 2 times of amount extracting n-butyl alcohols 4 times, merging n-butanol
Extract is reclaimed and is done as Chinese medical extract components group；
(3) Chinese medical extract constituent analysis：The chemical composition of Chinese medical extract is analyzed with HPLC-MS, mainly by Paeoniflorin
Class, tannin class, Paeonol glycoside, Anthraquinones, stilbene class, saponins and iridoid glycosides 33 are into being grouped into.
Embodiment 3：The extracting method of the Chinese medical extract components group for the treatment of hemorrhagic stroke, extraction step are as follows：
(1) bulk drug：5 parts of rheum officinale, 5 parts of the root bark of tree peony, 5 parts of the radix paeoniae rubrathe, 8 parts of the dried rhizome of rehmannia, 6 parts of pseudo-ginseng；
(2) above-mentioned raw materials medicinal powder is broken to into 40 mesh, plus 15 times of amount water is extracted twice, merging filtrate, be concentrated into 1.5g crude drugs/
Ml, is extracted 6 times with 3 times of amount dichloromethane, abandons dichloromethane layer, and water layer is again with 3 times of amount extracting n-butyl alcohols 6 times, merging n-butanol
Extract is reclaimed and is done as Chinese medical extract components group；
(3) Chinese medical extract constituent analysis：The chemical composition of Chinese medical extract is analyzed with HPLC-MS, mainly by Paeoniflorin
Class, tannin class, Paeonol glycoside, Anthraquinones, stilbene class, saponins and iridoid glycosides 33 are into being grouped into.
Claims (2)
1. a kind of extracting method for treating hemorrhagic stroke Chinese medical extract components group, extraction step are as follows：
（1）Bulk drug：Rheum officinale 1-5 parts, root bark of tree peony 1-5 parts, radix paeoniae rubrathe 1-5 parts, dried rhizome of rehmannia 1-8 parts, pseudo-ginseng 1-6 parts；
（2）Above-mentioned raw materials medicinal powder is broken to into 20-40 mesh, plus 5-15 times is measured water and extracted twice, merging filtrate is concentrated into 0.5-1.5g
Crude drug/ml, measures dichloromethane with 1-3 times and extracts 3-6 time, abandon dichloromethane layer, and water layer measures extracting n-butyl alcohol 3- with 1-3 times again
6 times, merge butanol extraction liquid recovery and do as Chinese medical extract components group；
（3）Chinese medical extract constituent analysis：The chemical composition of Chinese medical extract is analyzed with HPLC-MS, mainly by Chinese herbaceous peony glycoside, tan
Matter class, Paeonol glycoside, Anthraquinones, stilbene class, saponins and iridoid glycosides 33 are into being grouped into.
2. application of the Chinese medical extract components group as claimed in claim 1 in treatment hemorrhagic stroke medicine is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410734891.3A CN104435318B (en) | 2014-12-04 | 2014-12-04 | A kind of extracting method for treating hemorrhagic stroke Chinese medical extract components group and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410734891.3A CN104435318B (en) | 2014-12-04 | 2014-12-04 | A kind of extracting method for treating hemorrhagic stroke Chinese medical extract components group and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104435318A CN104435318A (en) | 2015-03-25 |
| CN104435318B true CN104435318B (en) | 2017-03-29 |
Family
ID=52882579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410734891.3A Expired - Fee Related CN104435318B (en) | 2014-12-04 | 2014-12-04 | A kind of extracting method for treating hemorrhagic stroke Chinese medical extract components group and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104435318B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107213251B (en) * | 2017-06-08 | 2018-07-31 | 广州得效生物科技有限公司 | A kind of Chinese medicine composition and preparation method thereof prevented and/or treat cardiovascular and cerebrovascular disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101721572B (en) * | 2009-12-30 | 2011-05-25 | 南京中医药大学 | Traditional Chinese medicine compound preparation for treating hemorrhagic apoplexy, preparation method and application thereof |
| CN104491143A (en) * | 2014-12-04 | 2015-04-08 | 南京中医药大学 | Extraction method and application of traditional Chinese medicine extract ingredient group for treating psoriasis |
-
2014
- 2014-12-04 CN CN201410734891.3A patent/CN104435318B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN104435318A (en) | 2015-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Auyeung et al. | Astragalus membranaceus: a review of its protection against inflammation and gastrointestinal cancers | |
| Geng et al. | Discrimination of raw and vinegar-processed Genkwa Flos using metabolomics coupled with multivariate data analysis: a discrimination study with metabolomics coupled with PCA | |
| Zhao et al. | Structure characterization and identification of steroidal saponins from the rhizomes of Anemarrhena asphodeloides by ultra performance liquid chromatography and hybrid quadrupole time-of-flight mass spectrometry | |
| Wei et al. | Analysis of chemical and metabolic components in traditional Chinese medicinal combined prescription containing Radix Salvia miltiorrhiza and Radix Panax notoginseng by LC‐ESI‐MS methods | |
| Peng-Peng et al. | Metabolomics analysis and rapid identification of changes in chemical ingredients in crude and processed Astragali Radix by UPLC-QTOF-MS combined with novel informatics UNIFI platform | |
| Wei et al. | GUO De-An. Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula | |
| Xiao et al. | A pre-classification strategy for identification of compounds in traditional Chinese medicine analogous formulas by high-performance liquid chromatography–Mass spectrometry | |
| Fan et al. | Identification of the absorbed components and metabolites of Xiao-Ai-Jie-Du decoction and their distribution in rats using ultra high-performance liquid chromatography/quadrupole time-of-flight mass spectrometry | |
| Huang et al. | Chemical profiling and antidiabetic potency of Paeonia delavayi: Comparison between different parts and constituents | |
| Ma et al. | Identification of major xanthones and steroidal saponins in rat urine by liquid chromatography–atmospheric pressure chemical ionization mass spectrometry technology following oral administration of Rhizoma Anemarrhenae decoction | |
| Borjigin et al. | Extraction, purification, structural characterization and biological activity of polysaccharides from Fritillaria: A review | |
| Han et al. | Absorption, metabolism and effect of compatibility on absorption of qishenyiqi dropping pill | |
| Zhou et al. | A strategy for rapid discovery of traceable chemical markers in herbal products using MZmine 2 data processing toolbox: A case of Jing Liqueur | |
| Zeng et al. | A review on the chemical profiles, quality control, pharmacokinetic and pharmacological properties of Fufang Xueshuantong Capsule | |
| CN104435318B (en) | A kind of extracting method for treating hemorrhagic stroke Chinese medical extract components group and application | |
| Song et al. | Mechanism exploration of ancient pharmaceutic processing (Paozhi) improving the gastroprotective efficacy of Aucklandiae Radix | |
| CN111454321A (en) | Method for separating and preparing high-purity saponin compound from paris polyphylla stems and leaves | |
| CN115453035B (en) | Method for extracting high-content notoginsenoside R1 from pseudo-ginseng | |
| CN106674312A (en) | Separation and purification method for high-purity monomer sweroside series components | |
| Xue et al. | Discovery of minor quality evaluation marker compounds for Chinese patent medicine products using a two-leveled metabolomics strategy | |
| CN104547026B (en) | Preparation method and application of salvia miltiorrhiza leave pseudo-ginseng extract | |
| CN104587103B (en) | A kind of extracting method that treating hemorrhagic stroke traditional medicine volatile oil extract component group and its application | |
| CN104491143A (en) | Extraction method and application of traditional Chinese medicine extract ingredient group for treating psoriasis | |
| Kong et al. | Study on the Compositional Analysis, Extraction Process, and Hemostatic and Anti-Inflammatory Activities of Cirsium japonicum Fisch. ex DC.–Cirsium setosum (Willd.) MB Extracts | |
| Guan et al. | A novel strategy for the multi-components division and discovering pharmacodynamic material basis of Chinese herbal compounds: A case study of Xian-Ling-Gu-Bao capsule |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170329 Termination date: 20181204 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |